News
Pfizer Strikes Deal With China's 3SBio
Digest more
16hon MSN
Pfizer closes a deal on a new Cancer drug. The stock is pacing for 4th day of gains. The Investment Committee debate the ...
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.
Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...
Explore more
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.
The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...
The Pfizer Middle East, Russia and Africa (MERA) Maternal Immunization Summit: Born Ready brought together more than 80 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results